Corporate News, Acquisitions: Herbalife Ltd, 3D Systems Corporation, Federal National Mortgage Association, Galena Biopharma

 Corporate News, Acquisitions: Herbalife Ltd, 3D Systems Corporation, Federal
 National Mortgage Association, Galena Biopharma Inc, Oncomed Pharmaceuticals

PR Newswire

NEW YORK, December 4, 2013

NEW YORK, December 4, 2013 /PRNewswire/ --

Market Buzz Report, provides daily stock updates, highlights notable stock
news for Herbalife Ltd.(NYSE:HLF), 3D Systems Corporation(NYSE:DDD), Federal
National Mortgage Association(OTCBB:FNMA), Galena Biopharma Inc(NASDAQ:GALE),
Oncomed Pharmaceuticals Inc(NASDAQ:OMED).

Herbalife Ltd.(NYSE:HLF) bulls get (more) good news this afternoon as a
Belgian appeals court has apparently overturned a previous ruling that found
the company was in operation of an pyramid scheme. The company says it has
"always believed that the first judgment contained factual errors and was
based on misinterpretations of its direct-selling sales method, and was
confident that the original judgment would be overturned on appeal."

Free Urgent Insider Catalyst Report ForHLFAvailable Here: Copy and paste the URL
into your browser)

3D Systems Corporation(NYSE:DDD) has unveiled two new printers for its
high-end ProJet line: the 4500 and 5500X. The former is called "the first and
only continuous-tone, full-color plastic 3D printer available on the market,"
and the latter is said to print objects featuring "the highest quality, most
accurate and toughest multi-material composites." (PRs: I, II)3D adds the 4500
prints semi-rigid plastic parts on a pixel-by-pixel basis in "high-resolution,
pantone-like color," and that the 5500X prints twice as fast and produces 60%
more volume than rival printers.The 4500 uses 3D's ColorJet Printing platform,
and the 5500X its MultiJet Printing platform. Both are the fruits of an R&D
budget that has grown rapidly as of late, following criticism 3D hasn't been
spending enough on product development. Though its consumer/enthusiast-focused
Cube printer line gets more press, the ProJet line still accounts for a much
larger portion of 3D's printer sales.

Free Urgent Insider Catalyst Report For DDD Available Here: Copy and paste the URL
into your browser)

"In the long history of bailout deals, no heist of the U.S. taxpayer would
approach this one in cynicism and chutzpah," writes Jonathan Laing of Bruce
Berkowitz's buyout plan for Federal National Mortgage Association (OTCBB:FNMA)
and Freddie (FMCC). One analyst calls it a "three-card monte" scheme in which
the preferred holders want taxpayers to pay them off at par, or turn over the
keys to the companies wildly valuable operations for little more than a $17B
rights offering. Yes, Treasury will have realized $187B in dividends from the
GSEs by year end - equal to the amount of the bailout - but that's "merely
fair recompense for the enormous risks taxpayers took." Also, more than $80B
of the $187B is the write-up of deferred tax assets - it will only be realized
if the companies operate profitably for many years, says Laing.

Free Urgent Insider Catalyst Report For FNMA Available Here: Copy and paste the URL
into your browser)

Shares of Galena Biopharma Inc(NASDAQ:GALE) are trading sharply higher.
Perhaps helping to tip sentiment is SA contributor Stock Investor, who is
upbeat on NeuVax, calling the outlook for the breast cancer vaccine
"tremendous."The author also thinks "the launch of Abstral in the U.S. will
help to fund the GALE pipeline and could have the potential to be a large
revenue generator."

Free Urgent Insider Catalyst Report For GALE Available Here: Copy and paste the URL
into your browser)

Oncomed Pharmaceuticals Inc(NASDAQ:OMED) announces a development and
commercialization agreement with Celgene (CELG). The deal includes demcizumab
and "up to six anti-cancer stem cell product candidates."OMED gets $177.25M
upfront ($22.25M equity investment).OMED also keeps "global co-development and
U.S. co-commercialization rights for five of the six anti-CSC product
candidates with 50/50 U.S. profit sharing, and royalties to be received in
other territories."CELG has an exclusive option on demcizumab subsequent to
which OMED will "co-develop [the drug and] share global development costs on a
1/3 OMED and 2/3 CELG basis."

Free Urgent Insider Catalyst Report ForOMEDAvailable Here: Copy and paste the URL
into your browser) is an investment community that Focuses on MicroCap
Securities. is an authorative authentic Google News Site and
Leading Provider of Investment Awareness and Featured Company Profiles. If
you would like more information regarding our news coverage solutions, please
visit  for more details. Get an edge on the
market with our Premium News Alerts  that are FREE for a limited time at Follow us on Facebook: Sign up for our FREE SMS News alerts
delivered directly to your mobile phone by texting the word PREPROMO to 27126.
(SMS alerts are free, however data rates may apply, check your wireless plan
for details.)

DISCLAIMER: FNNewswire (FNNW) is a third party publisher and news
dissemination service provider, which disseminates electronic information
through multiple online media channels. FNNW is NOT affiliated in any manner
with MarketBuzz Reports, or any company mentioned herein.
The commentary, views and opinions expressed in this release by MarketBuzz
Reports and are solely those of the MarketBuzz Reports & and are not shared by and do not reflect in any manner the
views or opinions of FNNW. The companies that are discussed herein may or may
not have approved the statements made in this release. FNNW is not liable for
any investment decisions by its readers or subscribers FNNW and its affiliated
companies are a news dissemination and financial marketing solutions provider
and are NOT a registered broker/dealer/analyst/adviser, holds no investment
licenses and may NOT sell, offer to sell or offer to buy any security. FNNW
was not compensated by any public company mentioned herein to disseminate this
press release.


This release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E the
Securities Exchange Act of 1934, as amended and such forward-looking
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. "Forward-looking statements"
describe future expectations, plans, results, or strategies and are generally
preceded by words such as "may", "future", "plan" or "planned", "will" or
"should", "expected," "anticipates", "draft", "eventually" or "projected". You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events, or results to
differ materially from those projected in the forward-looking statements,
including the risks that actual results may differ materially from those
projected in the forward-looking statements as a result of various factors,
and other risks identified in a company's annual report on Form 10-K or 10-KSB
and other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance on
such statements. The forward-looking statements in this release are made as of
the date hereof and FNNW undertakes no obligation to update such statements.

FNNW Contact Information:
Company: FN Newswire
Contact email:
U.S. Phone:+1(954)345-0611
SOURCE: FNMedia Group, LLC

SOURCE FN Media Group, LLC
Press spacebar to pause and continue. Press esc to stop.